<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Psychiatry</journal-id><journal-id journal-id-type="publisher-id">IJPS</journal-id><journal-title-group><journal-title>Iranian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1735-4587</issn><issn pub-type="epub">2008-2215</issn><publisher><publisher-name>Psychiatry &#x00026; Psychology Research Center, Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27928252</article-id><article-id pub-id-type="pmc">5139955</article-id><article-id pub-id-type="publisher-id">IJPS-11-191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of Passion Flower Extract, as an Add-On Treatment to Sertraline, on Reaction Time in Patients &#x0200e;with Generalized Anxiety Disorder: A Double-Blind Placebo-Controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nojoumi</surname><given-names>Mandana</given-names></name><degrees>Pharm.D</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ghaeli</surname><given-names>Padideh</given-names></name><degrees>Pharm.D</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Salimi</surname><given-names>Samrand</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Ali</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Raisi</surname><given-names>Firoozeh</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label><bold>&#x0200e;</bold>Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University of Pharmaceutical &#x0200e;Sciences, Tehran, Iran.</aff><aff id="aff2"><label>2</label>Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, &#x0200e;Tehran, Iran.</aff><aff id="aff3"><label>3</label>Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran. </aff><aff id="aff4"><label>4</label>Research Centre for Intelligent Signal Processing, Tehran, Iran.</aff><aff id="aff5"><label>5</label>Psychiatric and Psychology Research Centre, Roozbeh Psychiatric Hospital, Tehran University of &#x0200e;Medical Sciences, Tehran, Iran. </aff><author-notes><corresp id="cor">Corresponding author: Samrand Salimi, MD. Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran. 
Tel: +98 21 22904887. Fax: +98 21 22904887
<email>salimisamrand@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>11</volume><issue>3</issue><fpage>191</fpage><lpage>197</lpage><permissions><copyright-statement>Copyright &#x000a9; Psychiatry &#x00026; Psychology Research Center, Tehran University of Medical Sciences</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Objective: </bold>Because of functional impairment caused by generalized anxiety disorder and due to cognitive side &#x0200e;effects of many anti-anxiety agents, in this study we aimed to evaluate the influence of Passion &#x0200e;flower standardized extract on reaction time in patients with generalized anxiety disorder.&#x0200e;</p><p>
<bold>Method: </bold>Thirty patients aged 18 to 50 years of age, who were diagnosed with generalized anxiety disorder and &#x0200e;fulfilled the study criteria, entered this double-blind placebo-controlled study. Reaction time was &#x0200e;measured at baseline and after one month of treatment using computerized software. Correct &#x0200e;responses, omission and substitution errors and the mean time of correct responses (reaction time) in &#x0200e;both visual and auditory tests were collected. The analysis was performed between the two groups &#x0200e;and within each group utilizing SPSS PASW- statics, Version 18. P-value less than 0.05 was &#x0200e;considered statistically significant.&#x0200e;</p><p>
<bold>Results: </bold>All the participants were initiated on Sertraline 50 mg/day, and the dosage was increased to 100 &#x0200e;mg / day after two weeks. Fourteen patients received Pasipy (Passion Flower) 15 drops three times &#x0200e;daily and 16 received placebo concurrently. Inter-group comparison proved no significant difference &#x0200e;in any of the test items between assortments while a significant decline was observed in auditory &#x0200e;omission errors in passion flower group after on month of treatment using intra-group analysis.&#x0200e;&#x0200e;</p><p>
<bold>Conclusion: </bold>This study noted that passion flower might be suitable as an add-on in the treatment of generalized &#x0200e;anxiety disorder with low side effects. Further studies with longer duration are recommended to &#x0200e;confirm the results of this study.&#x0200e;</p></abstract><kwd-group><title>Key Words</title><kwd><italic>Generalized Anxiety Disorder</italic></kwd><kwd><italic>Mental Processing</italic></kwd><kwd><italic>Passion Flower</italic></kwd><kwd><italic>Reaction Time</italic></kwd><kwd><italic>Sertraline</italic>&#x0200e;</kwd></kwd-group></article-meta></front><body><p>The Generalized Anxiety Disorder (GAD) is defined as the basic anxiety disorder, which may reflect &#x0200e;the fundamental process of all emotional disorders and significant degree of functional &#x0200e;impairment (<xref rid="B1" ref-type="bibr">1</xref>). GAD is hyper-reactivity and a fear of negative emotional shifts and &#x0200e;unmanageable worry about preventing these perceptive contrasts (<xref rid="B2" ref-type="bibr">2</xref>). The symptoms are difficult &#x0200e;to control and last for more than six months. GAD is associated with three or more of diagnostic &#x0200e;items from DSM-IV (Diagnostic and Statistical manual of Mental illnesses-4th edition) including: &#x0200e;Feeling keyed up or on edge, easily getting fatigue, mind going blank, agitation, somatic tension &#x0200e;and sleep disturbances. Treatment choices include psychological therapies such as cognitive &#x0200e;behavioral therapy (CBT) as the main non-pharmacological therapy (<xref rid="B3" ref-type="bibr">3</xref>), acceptance and &#x0200e;commitment therapy (<xref rid="B4" ref-type="bibr">4</xref>), intolerance of uncertainty therapy and motivational interviewing (<xref rid="B5" ref-type="bibr">5</xref>) as &#x0200e;well as pharmacotherapy including Selective Serotonin Reuptake Inhibitors (SSRIs) (<xref rid="B6" ref-type="bibr">6</xref>), Benzodiazepines (<xref rid="B7" ref-type="bibr">7</xref>), Pregabalin (<xref rid="B8" ref-type="bibr">8</xref>) and &#x0200e;Gabapentin (<xref rid="B9" ref-type="bibr">9</xref>), Tricyclic Antidepressants (TCAs), Buspirone and Hydroxyzine (<xref rid="B6" ref-type="bibr">6</xref>). Reaction Time (RT) is defined as the time &#x0200e;elapsed between offering stimuli and the indication of comprehension by the subject (<xref rid="B10" ref-type="bibr">10</xref>). RT is &#x0200e;claimed to be the main dependent variable for analyzing perceptive models (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Response procedure is directly based on circumstances (<xref rid="B12" ref-type="bibr">12</xref>). Many factors may be responsible for &#x0200e;reaction time fluctuations, specially a great number of drugs and substances e.g., Caffeine (<xref rid="B13" ref-type="bibr">13</xref>), &#x0200e;alcohol (<xref rid="B14" ref-type="bibr">14</xref>), psychostimulants (<xref rid="B15" ref-type="bibr">15</xref>), sedative-hypnotic and anti-epileptic drugs (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>) and many &#x0200e;of cognitive side effects, which are raised by psychiatric pharmacotherapies (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>).</p><p>&#x0200e;Passion flower symbolizes the passion of Jesus in Christian theology because of its unique &#x0200e;structure (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>&#x0200e;Traditionally its extract has been used as an herbal remedy for nervous anxiety (<xref rid="B21" ref-type="bibr">21</xref>) and &#x0200e;insomnia, tenderness, restlessness, irritability (<xref rid="B22" ref-type="bibr">22</xref>) and hysteria (<xref rid="B23" ref-type="bibr">23</xref>). Passion flower has been &#x0200e;reported to affect GAD (<xref rid="B24" ref-type="bibr">24</xref>). Most of these effects are believed to be related to benzoflavone, &#x0200e;which is the active constituent of the plant extract (<xref rid="B25" ref-type="bibr">25</xref>). We aimed to investigate the effects of &#x0200e;passion flower extract on perceptual processing toward threats via reaction time test since its &#x0200e;advantage on mental function did not receive specific reflections in previous studies.&#x0200e;&#x0200e;</p><sec><title>Materials and Method</title><p>
<bold><italic>Research Participants</italic></bold>
</p><p>Thirty outpatients entered this randomized double-blind placebo-controlled study (Ethical &#x0200e;approval number 7408 - by Ethics Committee at Islamic Azad University of Pharmaceutical &#x0200e;Sciences). The participants were included in the study from Roozbeh and Baharloo hospitals and &#x0200e;private psychiatric offices during 2010- 2012. Patients were diagnosed with Generalized Anxiety &#x0200e;Disorder (GAD) based on DSM-IV criteria and clinical interviews. Their family history was &#x0200e;considered as well. They were tested using Hamilton Anxiety Rating Scale Form A (HARS). &#x0200e;Hamilton Rating Scale for Depression (HRSD) was utilized to determine the patients&#x02019; comorbid &#x0200e;depression. The Hamilton Scales were standardized for Iranian patients.</p><p>Patients between 18 to 24 years of age were included. In addition, sertraline consumption was &#x0200e;considered the best treatment for their current disease per decision of the psychiatrist. All patients &#x0200e;were initiated on Sertraline. The exclusion criteria were as follows: Having difficulty including &#x0200e;allergic reactions to sertraline or active ingredients of passion flower, renal or hepatic impairment, &#x0200e;age under 18, pregnancy and lactation, consuming Warfarin, Hexobarbital, Pantobarbital, &#x0200e;Levothyroxine or other thyroid medications, using alcohol or hallucinogens and history of &#x0200e;tachycardia. The patients with a history of kidney or liver dysfunction were excluded. An &#x0200e;informed consent was obtained from the patients prior to the initiation of the examination. &#x0200e;</p><p>
<bold><italic>Medication</italic></bold>
</p><p>The first-line treatment for GAD patients was 50 mg Sertraline tablet for both groups. Pasipy&#x000ae; Drop - Iran Darouk Co. was the standardized hydroalcoholic extract of passion flower as &#x0200e;an add-on therapy. </p><p>Placebo consisted of 20% aqueous solution of absolute edible alcohol and natural coloring &#x0200e;agents. The placebo mixture was filled in amber glass bottles with dropper identical to the drug &#x0200e;container.&#x0200e;</p><p>
<bold><italic>Assortment</italic></bold>
</p><p>The participants were randomly assigned into two groups to receive either Sertraline + Pasipy (S-&#x0200e;drug group), or Sertraline + placebo (S-placebo group) for one month. All patients were initiated on &#x0200e;Sertraline 50 mg/day; the dosage was increased to 100 mg/day after two weeks. Pasipy and its &#x0200e;placebo were given at 15 drops three times daily.&#x0200e;</p><p>
<bold><italic>Data Collection Tools</italic></bold>
</p><p>The Reaction Time (RT) test was utilized as the standard computerized software. These process &#x0200e;measured psycho-neural responses toward visual and auditory stimuli. The input variables &#x0200e;were the number of correct responses, omission and substitution errors and the mean time of &#x0200e;correct responses (mean reaction time) (<xref rid="B26" ref-type="bibr">26</xref>). After receiving each of the visual or auditory stimuli, the participants were asked to hit the correct keys, which were designed on a computer &#x0200e;keyboard. The sign on each key was related to a specific visual or auditory threat in the tests. The &#x0200e; stimuli were presented continuously on the screen during the test procedure. Correct responses &#x0200e;were made when the participants had chosen the key that was the same as the presented stimulus, &#x0200e;whereas choosing an incorrect answer was considered as a substitution error. When the patient &#x0200e;ignored a visual or auditory stimuli, the answer was recorded as an omission error. Reaction &#x0200e;time was the mean time of correct responses to stimuli in each of the visual or auditory tests. &#x0200e;Test items were measured at baseline and after one month of S-drug or S-placebo administration. &#x0200e;A questionnaire of adverse effects or possible drug interactions was filled at the end of the study.&#x0200e;</p><p>
<bold><italic>Statistical Analysis</italic></bold>
</p><p>Demographic characteristics were compared between the two groups. The RT test outputs were analyzed once in comparison between S-drug and S-placebo groups &#x0200e;using independent sample t-test (inter-group comparison); then reaction time changes after one &#x0200e;month was determined in each group using a paired sample t-test (intra-group comparison). &#x0200e;Scores from the Hamilton anxiety scale form A (HAM-A) were compared between S-drug and S-&#x0200e;placebo groups using an independent sample t-test. The aim was to reconfirm the positive effect &#x0200e;of passion flower on GAD and the possible improvement of the add-on therapy encountered with &#x0200e;the SSRI monotherapy. All the comparisons were performed utilizing SPSS software (PASW &#x02013; &#x0200e;statistics 18). A p-value of less than 0.05 was considered as the minimal level of statistical &#x0200e;significance in all measures.&#x0200e;</p></sec><sec sec-type="results"><title>Results</title><p>Seventy patients were selected for the study; of whom, 24 were excluded as they did not meet our &#x0200e;criteria, and 16 did not follow the medication protocol because of low compliance and drug &#x0200e;incompatibility. The patients who met the inclusion criteria were randomized by permeated block &#x0200e;randomization (<xref ref-type="table" rid="T1">Table 1</xref>).&#x0200e;</p><table-wrap id="T1" position="float"><label>Table1</label><caption><p>Demographic characteristics of patients in both groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Group</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + drug</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + placebo</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="2" colspan="1">
<bold>P-value</bold>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Item</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>N = 14</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>N = 16</bold>
</th></tr></thead><tbody><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Age(mean&#x000b1;SD <xref ref-type="table-fn" rid="TFN1">&#x000b6;</xref>)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">29.07 &#x000b1; 8.60</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">32.19 &#x000b1; 11.43</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.410</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Gender (Percent)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">F: 85.7% - M: 14.3%</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">F: 87.5% - M: 12.5%</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.891</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Caffeine intake (mg/day)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">173.54 &#x000b1; 99.17</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">130.46 &#x000b1; 67.98</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.203</td></tr></tbody></table><table-wrap-foot><p>*: Significant difference (P-value &#x0003c; 0.05)</p><fn id="TFN1"><label>&#x000b6;</label><p> SD: Standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table2</label><caption><p>Comparison of Reaction time parameters between the Two study Groups after One Month</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Group</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + drug N = 14</bold>
<bold>&#x0200e;</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + placebo N = 16</bold>
<bold>&#x0200e;</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Visual test</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
<xref ref-type="table-fn" rid="TFN2">&#x000b6;</xref>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.43 &#x000b1; 6.00</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">9.69 &#x000b1; 0.09</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.663</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.57 &#x000b1; 4.85</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.19 &#x000b1; 4.04</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.153</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">11.00 &#x000b1; 5.94</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">12.13 &#x000b1; 7.90</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.666</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.65 &#x000b1; 0.12</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.64 &#x000b1; 0.12</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.720</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Auditory test</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">3.64 &#x000b1; 1.69</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.25 &#x000b1; 3.51</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.561</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.93 &#x000b1; 5.84</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.44 &#x000b1; 4.94</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.216</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">15.43 &#x000b1; 6.76</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">17.31 &#x000b1; 7.43</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.476</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.49 &#x000b1; 0.12</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.55 &#x000b1; 12</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.467</td></tr></tbody></table><table-wrap-foot><p>*: Significant difference (P-value &#x0003c; 0.05)</p><fn id="TFN2"><label>&#x000b6;</label><p>SD: Standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table3</label><caption><p>Comparison of Reaction time parameters within each study group at baseline (1) and after One Month (2)</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Group</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + drug</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + placebo</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
<hr/>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Visual test</th><th style=" color:#000000;" align="center" valign="middle" colspan="2" rowspan="1">
<bold>Mean &#x000b1; SD</bold>
<xref ref-type="table-fn" rid="TFN4">&#x000b6;</xref>
</th><th style=" color:#000000;" align="center" valign="middle" colspan="2" rowspan="1">
<bold>Mean &#x000b1; SD</bold>
</th></tr></thead><tbody><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">9.21 &#x000b1; 7.99</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.555</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.69 &#x000b1; 8.24</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.323</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.43 &#x000b1; 6.00</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">9.69 &#x000b1; 9.09 &#x000a0;</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">9.14 &#x000b1; 3.84</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.222</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.50 &#x000b1; 4.82</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.808</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.57 &#x000b1; 4.85</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.19 &#x000b1; 4.04 &#x000a0;</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">11.64 &#x000b1; 6.79</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.585</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.81 &#x000b1; 7.31</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.340</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">11.00 &#x000b1; 5.94</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">12.13 &#x000b1; 7.90 &#x000a0;</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time <xref ref-type="table-fn" rid="TFN5">1</xref> (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.59 &#x000b1; 0.21</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.288</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.61 &#x000b1; 0.21</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.549</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time <xref ref-type="table-fn" rid="TFN6">2</xref> (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.64 &#x000b1; 0.11</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.64 &#x000b1; 0.12</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Auditory test</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>mean &#x000b1; SD</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">3.36 &#x000b1; 1.45</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.537</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.19 &#x000b1; 4.86</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.939</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Correct responses <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">3.64 &#x000b1; 1.69</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.25 &#x000b1; 3.51</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.71 &#x000b1; 4.39</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.69 &#x000b1; 4.76</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.845</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Substitution errors <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">10.93 &#x000b1; 5.84</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.44 &#x000b1; 4.94</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors <xref ref-type="table-fn" rid="TFN5">1</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.71 &#x000b1; 4.39</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.045 <xref ref-type="table-fn" rid="TFN3">*</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">17.13 &#x000b1; 6.11</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.898</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Omission errors <xref ref-type="table-fn" rid="TFN6">2</xref></td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">15.43 &#x000b1; 6.76</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">17.31 &#x000b1; 7.43</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time <xref ref-type="table-fn" rid="TFN5">1</xref> (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.44 &#x000b1; 0.16</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.484 </td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.60 &#x000b1; 0.16</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.312</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Mean response time <xref ref-type="table-fn" rid="TFN6">2</xref> (second)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.49 &#x000b1; 0.21</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.54 &#x000b1; 0.18</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p>: Significant difference (P-value &#x0003c; 0.05)</p></fn><fn id="TFN4"><label>&#x000b6;</label><p>SD: Standard deviation</p></fn><fn id="TFN5"><label>1</label><p>: baseline</p></fn><fn id="TFN6"><label>2</label><p>&#x0200e;&#x0200e; : One month after drug or placebo consumption</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table4</label><caption><p>Comparison of Hamilton Anxiety Rating Scale Form (HARS) at Baseline between the Two Study Groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Group</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + drug N = 14</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + placebo N = 16</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Score</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Mean &#x000b1; SD </bold>
<xref ref-type="table-fn" rid="TFN8">&#x000b6;</xref>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Mean &#x000b1; SD</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Baseline</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">21.54 &#x000b1; 8.15</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">24.07 &#x000b1; 10.73</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.495</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">After 1 month</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">16.44 &#x000b1; 7.15</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">23.08 &#x000b1; 8.85</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.039 <xref ref-type="table-fn" rid="TFN7">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>*</label><p>: Significant difference (P-value &#x0003c; 0.05)</p></fn><fn id="TFN8"><label>&#x000b6;</label><p> SD: Standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table5</label><caption><p>List of Reported Adverse Effects by Patients in Both Study Groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Group</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + drug</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>N = 14</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sertraline + placebo</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>N = 16</bold>
<hr/>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Item</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Frequency</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Percent</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Frequency</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Percent</bold>
</th><th style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Allergy</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.925</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Asthma</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.925</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Sinus irritation</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.925</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Dermatitis</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.634</bold>
</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Subcutaneous phlebitis</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">NS</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Tachycardia</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.861</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Nausea</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>7</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>20.6%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.319</bold>
</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Vomiting</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>5.9%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.165</bold>
</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Dizziness</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>5</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>14.7%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>5.9%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.155</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Somnolence</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>23.5%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>7</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>20.6%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.481</bold>
</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Excessive sedation</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>5.9%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.493</bold>
</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Abnormal bleeding</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">2.9 %</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.333</td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">etc.</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>3</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>8.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>4</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>11.8%</bold>
</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.825</bold>
</td></tr></tbody></table></table-wrap><p>Fourteen patients (85.7% female and 14.3% male) were initiated on Sertraline (50 mg/day and &#x0200e;the dosage was increased to 100 mg/day after two weeks) + Pasipy (15 drops three times daily). &#x0200e;The mean age &#x000b1; standard deviation (SD) of these patients was 29.07 &#x000b1; 8.60. Sixteen patients &#x0200e;&#x0200e;(87.5% female and 12.5% male) were initiated on Sertraline (50 mg/day and the dosage was &#x0200e;increased to 100 mg/day after two weeks) + placebo (15 drops three times daily). The mean age in &#x0200e;this group was 32.19 &#x000b1; 11.43.&#x0200e;</p><p>
<bold><italic>Inter-group analysis</italic></bold>
</p><p>After one month, independent sample t-test did not demonstrate any significant difference in any &#x0200e;of visual or auditory items. Baseline scores were proved not to be statistically different, but they &#x0200e;are not displayed in the tables. In the visual test for the drug group, the omission errors were less &#x0200e;than the placebo consumers, but this difference was not statistically significant (P = 0.666). &#x0200e;However, the mean reaction time was slightly longer in this group (P = 0.720).</p><p> &#x0200e;In auditory analysis for the drug group, omission errors were less than the placebo group, but the &#x0200e;difference was not significant (P = 0.476). However, the mean reaction time toward sound threats &#x0200e;improved slightly after one month of taking Pasipy in the drug group compared to the placebo &#x0200e;group (P = 0.467) (<xref ref-type="table" rid="T2">Table 2</xref>).&#x0200e;</p><p>
<bold><italic>Intra-group Analysis</italic></bold>
</p><p>In the drug group, a significant decline in auditory omission errors was observed after one month &#x0200e;of treatment (P = 0.045). The mean reaction time had a non-significant increase in both visual (P &#x0200e;&#x0200e;= 0.288) and auditory tests (P = 0.484) in drug intra-group analysis. None of the changes in test &#x0200e;variables in placebo consumers reached the significant level. The mean reaction time was a bit &#x0200e;longer in the visual test (P = 0.549), but had a non-significant improvement toward auditory &#x0200e; stimuli in this group (P = 0.312) (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>
<bold><italic>Hamilton Test</italic></bold>
</p><p>Hamilton Anxiety Rating Scale Form A (HARS) questionnaires were ranged between 18 to 24 (mild to moderate). A significant improvement to relieve anxiety symptoms was observed in the add-on therapy group compared to the Sertraline + placebo after one month of administration (P = 0.039) (<xref ref-type="table" rid="T4">Table 4</xref>).&#x0200e;</p><p>
<bold><italic>Adverse Reactions</italic></bold>
</p><p>Based on data from <xref ref-type="table" rid="T5">Table 5</xref>, no major and significant adverse effect or drug interaction was observed after Sertraline + Pasipy co-administration compared to the other group. The most remarkable side effect in Sertraline + placebo group was somnolence (F = 7, percent = 20.6%), which occurred more frequently in add-on therapy (F = 8, percent = 23.5%).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>&#x02018;Fear appeal&#x02019; is a brain message against threatening situations (<xref rid="B27" ref-type="bibr">27</xref>). It is a distinguishing &#x0200e;characteristic in anxiety disorders (<xref rid="B28" ref-type="bibr">28</xref>) which persuades the suffered patient to do a warily action. &#x0200e;This could explain reduced omission errors after add-on therapy. Therefore, passion flower seems &#x0200e;to increase the positive risky behavior and remove hesitance features as expected. It is &#x0200e;accompanied by the Hamilton test results that reconfirm the potential effects of this herbal &#x0200e;medicine for GAD. Slight and non-significant prolongation in mean response time (RT) is &#x0200e;explained by relieving pathological impulsiveness, which is one of the most distinguished features &#x0200e;of GAD (<xref rid="B29" ref-type="bibr">29</xref>). Numerous studies revealed that GAD rarely achieves high end-state functioning at &#x0200e;post-treatment, and the influence of these treatments on quality of life is not quite proved (<xref rid="B30" ref-type="bibr">30</xref>). &#x0200e;Pharmacotherapy has been claimed the main stage of treatment. Despite advantages, one of the &#x0200e;concerns about the first-line medication is cognitive side effects (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Among &#x0200e;Benzodiazepines, which are known as one of the most promising medications, the difficulty in &#x0200e;discontinuing these medications is a crucial dilemma (<xref rid="B1" ref-type="bibr">1</xref>). CBT has been believed to be the most &#x0200e;effective treatment in GAD among the non-pharmacological management. Studies that consider &#x0200e;CBT have some limitations; for instance, the inter-personal differences and long duration of such &#x0200e;experiments can restrict reaching confirmed conclusions (<xref rid="B33" ref-type="bibr">33</xref>). The pharmaceutical industry relies &#x0200e;on plant-based medicines significantly</p><p>(<xref rid="B34" ref-type="bibr">34</xref>). &#x0200e;Passion flower and its active ingredients, chrysin and pyrone derivative maltol, are responsible for &#x0200e;the related CNS effects (<xref rid="B35" ref-type="bibr">35</xref>). Although the exact pharmacological mechanism is not fully known, &#x0200e;the majority of studies indicated that the sedative-hypnotic effects of passion flower are &#x0200e;presented through gama aminobutyric acid (GABA) neurotransmission (<xref rid="B36" ref-type="bibr">36</xref>). In a study by Appel &#x0200e;et al., passion flower was shown to antagonize GABAB receptor. However, ethanol site and &#x0200e;benzodiazepine site of GABAA receptors were not affected (<xref rid="B37" ref-type="bibr">37</xref>). Passion flower has been &#x0200e;demonstrated to be an efficacious drug for GAD management when compared with Oxazepam &#x0200e;and its undesirable side effects. The most preferences for anxiolytic effect of this phytotherapy &#x0200e;compared to the chemical medications are the venial impairment of performance (<xref rid="B24" ref-type="bibr">24</xref>), lack of &#x0200e;psychomotor dysfunction (<xref rid="B38" ref-type="bibr">38</xref>) or high sedation (<xref rid="B39" ref-type="bibr">39</xref>), which are promising in comparison with &#x0200e;psychiatric drugs with many of cognitive side effects (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). The effects of cognitive function &#x0200e;have been reported in the literature. For example, in a study by Dimpfel et al., mathematical &#x0200e;calculation, concentration and memory tests were performed to evaluate the effects of passion &#x0200e;flower dry extract in a group of volunteers. The results showed no cognitive impairment even &#x0200e;though the psychometric scales were different from the RT test used in our study (<xref rid="B40" ref-type="bibr">40</xref>). Passion &#x0200e;flower 500 mg was administered before surgery and numerical rating scale (NRS) was utilized to &#x0200e;assess anxiety and sedation; besides, Trieger Dot Test and the Digit-Symbol Substitution were &#x0200e;used to evaluate psychomotor changes. The outcomes showed no significant difference in the &#x0200e;psychomotor function between the two groups after anesthesia (<xref rid="B41" ref-type="bibr">41</xref>). This study concluded that &#x0200e;passion flower does not affect reaction time, and therefore can be given to those patients whose &#x0200e;level of consciousness and speed of performance is important in their professional activities. In &#x0200e;our last trial, we found no adverse effect of passion flower on alertness in the healthy volunteers (<xref rid="B25" ref-type="bibr">25</xref>). However, small sample size and time limitation restricted our experiment. &#x0200e;</p></sec><sec><title>Limitations</title><p>The limitations of the present study were as following: Firstly, the sample size was relatively small. Secondly, one month may not be considered long enough to precisely evaluate the effects of Passion flower extract. Thirdly, "structured interview", a more precise mean of evaluation of the patients, was not utilized in this study.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This study noted that passion flower might be consumed as a safe (low side effects) add-on in the treatment of generalized &#x0200e;anxiety disorder. Further studies with longer duration are recommended to &#x0200e;confirm the results of this study.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors like to send special thanks to Dr Farshad Hashemian for his initiative role in starting and generous supervision throughout this study.</p></ack><sec><title>Conflict of interest</title><p>None.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>&#x0200e;Brown</surname><given-names>TA</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>TA</given-names></name><name><surname>Barlow</surname><given-names>DH</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Barlow</surname><given-names>DH</given-names></name></person-group><article-title>Generalized Anxiety Disorder</article-title><source>Clinical &#x0200e;Handbook of Psychiatry Disorders</source><year>2001</year><edition>3rd ed. </edition><publisher-loc>New York</publisher-loc><publisher-name>Guilford Publications</publisher-name><fpage>154</fpage><lpage>208</lpage><comment>Chapter 4</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>MG</given-names></name><name><surname>Llera</surname><given-names>SJ</given-names></name><name><surname>Erickson</surname><given-names>TM</given-names></name><name><surname>Przeworski</surname><given-names>A</given-names></name><name><surname>Castonguay</surname><given-names>LG</given-names></name></person-group><article-title>Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment</article-title><source> Annu Rev Clin Psychol</source><year>2013</year><volume>9</volume><fpage>275</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">23537486</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanrahan</surname><given-names>F</given-names></name><name><surname>Field</surname><given-names>AP</given-names></name><name><surname>Jones</surname><given-names>FW</given-names></name><name><surname>Davey</surname><given-names>GC</given-names></name></person-group><article-title>A meta-analysis of cognitive therapy for worry in generalized anxiety disorder</article-title><source> Clinical psychology review</source><year>2013</year><volume>33</volume><fpage>120</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">23168445</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Roemer</surname><given-names>L</given-names></name><name><surname>Orsillo</surname><given-names>SM</given-names></name></person-group><article-title>Expanding our conceptualization of and treatment for generalized &#x0200e;anxiety disorder: Integrating mindfulness/ acceptance-based approaches with existing cognitive-&#x0200e;behavioral models</article-title><source> Clin Psychol: Science and Practice</source><year>2006</year><volume>9</volume><fpage>54</fpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Hoyer</surname><given-names>J</given-names></name><name><surname>Van</surname><given-names>der Heiden C</given-names></name><name><surname>Portman</surname><given-names>ME</given-names></name></person-group><article-title>Psychotherapy for generalized anxiety disorder</article-title><source> &#x0200e;Psychiatr Ann</source><year>2011</year><volume>41</volume><fpage>87</fpage><lpage>94</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Wells</surname><given-names>BG</given-names></name><name><surname>Dipiro</surname><given-names>JT</given-names></name><name><surname>Schwinghammer</surname><given-names>TL</given-names></name><name><surname>Dipiro</surname><given-names>CV</given-names></name></person-group><source>Pharmacotherapy handbook</source><year>2009</year><publisher-loc>&#x0200e;United States of America</publisher-loc><publisher-name>The McGraw-Hill companies</publisher-name><fpage>740</fpage><lpage>747</lpage><comment>Section 13</comment></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Durham</surname><given-names>RC</given-names></name></person-group><article-title>Treatment of generalized anxiety disorder</article-title><source> Psychiatry</source><year>2007</year><volume>6</volume><fpage>183</fpage><lpage>187</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wensel</surname><given-names>TM</given-names></name><name><surname>Powe</surname><given-names>KW</given-names></name><name><surname>Cates</surname><given-names>ME</given-names></name></person-group><article-title>Pregabalin for the treatment of generalized anxiety disorder</article-title><source> Annals of Pharmacotherapy</source><year>2012</year><volume>46</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">22395254</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>&#x0200e;&#x0200e;El-Mallakh</surname><given-names>RS</given-names></name><name><surname>Ghaemi</surname><given-names>SN</given-names></name></person-group><source>Bipolar depression: A comprehensive guide</source><year>2007</year><publisher-loc> Arlington</publisher-loc><publisher-name>American Psychiatric &#x0200e;Pub.</publisher-name><lpage>158</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>HR</given-names></name><name><surname>Zanetti</surname><given-names>R</given-names></name><name><surname>Santos</surname><given-names>CCd</given-names></name><name><surname>Manzano</surname><given-names>GM</given-names></name><name><surname>Tierra-Criollo</surname><given-names>CJ</given-names></name></person-group><article-title>Current perception threshold and reaction time in the assessment of sensory peripheral nerve fibers through sinusoidal electrical stimulation at different frequencies</article-title><source> Revista Brasileira de Engenharia Biom&#x000e9;dica</source><year>2013</year><volume>29</volume><fpage>278</fpage><lpage>285</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ratcliff</surname><given-names>R</given-names></name></person-group><source>Parallel-processing mechanisms and processing of organized information in human memory. Parallel Models of Associative Memory: Updated Edition</source><year>2014</year><lpage>309</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>SD</given-names></name><name><surname>Heathcote</surname><given-names>A</given-names></name></person-group><article-title>The simplest complete model of choice response time: linear ballistic accumulation</article-title><source> Cognitive psychology</source><year>2008</year><volume>57</volume><fpage>153</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">18243170</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>HR</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Emde</surname><given-names>GG</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Coviella</surname><given-names>IL</given-names></name></person-group><article-title>The effects of low doses of caffeine on human performance and mood</article-title><source> Psychopharmacology</source><year>1987</year><volume>92</volume><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">3114783</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howland</surname><given-names>J</given-names></name><name><surname>Rohsenow</surname><given-names>DJ</given-names></name><name><surname>Arnedt</surname><given-names>JT</given-names></name><name><surname>Bliss</surname><given-names>CA</given-names></name><name><surname>Hunt</surname><given-names>SK</given-names></name><name><surname>Calise</surname><given-names>TV</given-names></name><etal/></person-group><article-title>The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time</article-title><source> Addiction</source><year>2011</year><volume>106</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">21134017</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Slezak</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>JL</given-names></name></person-group><article-title>An influence of delayed reinforcement on the effectiveness of &#x0200e;psychostimulants to enhance indices of attention under a five-choice serial reaction time &#x0200e;procedure in male rats</article-title><source> Exp Clin Psychopharmacol</source><year>2013</year><volume>21</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">24099356</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurado</surname><given-names>JL</given-names></name><name><surname>Fernandez-Mas</surname><given-names>R</given-names></name><name><surname>Fernandez-Guardiola</surname><given-names>A</given-names></name></person-group><article-title>Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects</article-title><source> Psychopharmacology</source><year>1989</year><volume>99</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">2506608</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hessen</surname><given-names>E</given-names></name><name><surname>Lossius</surname><given-names>MI</given-names></name><name><surname>Reinvang</surname><given-names>I</given-names></name><name><surname>Gjerstad</surname><given-names>L</given-names></name></person-group><article-title>Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy</article-title><source> Epilepsia</source><year>2006</year><volume>47</volume><fpage>2038</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">17201701</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demyttenaere</surname><given-names>K</given-names></name><name><surname>Jaspers</surname><given-names>L</given-names></name></person-group><article-title>Review: Bupropion and SSRI-induced side effects</article-title><source> J Psychopharmacol</source><year>2008</year><volume>22</volume><fpage>792</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">18308785</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>&#x0200e;Davies</surname><given-names>SJC</given-names></name><name><surname>Christmas</surname><given-names>DM</given-names></name></person-group><collab collab-type="editors">International College of &#x0200e;Affective Neuroscience</collab><article-title>Side-effects of Pregabalin treating generalized anxiety disorder &#x0200e;and social anxiety disorder: A systematic review and meta-analysis</article-title><source>2011 ICANS poster session abstract book</source><year>2011</year><publisher-loc>Florence</publisher-loc><publisher-name>International &#x0200e;master in affective neuroscience</publisher-name><fpage>17</fpage><lpage>18</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>&#x0200e;Viladesau</surname><given-names>R</given-names></name></person-group><source>The Beauty of the Cross: The Passion of Christ in Theology and the Arts from the Catacombs to the Eve of the Renaissance</source><year>2005</year><publisher-loc>City</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Anxiolytic activity of aerial and underground parts of Passiflora incarnata</article-title><source> Fitoterapia</source><year>2001</year><volume>72</volume><fpage>922</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">11731118</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krenn</surname><given-names>L</given-names></name></person-group><article-title>[Passion Flower (Passiflora incarnata L)--a reliable herbal sedative]</article-title><source> Wiener medizinische Wochenschrift (1946)</source><year>2002</year><volume>152</volume><fpage>404</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">12244887</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>K</given-names></name><name><surname>Rose</surname><given-names>T</given-names></name><name><surname>Fiebich</surname><given-names>B</given-names></name><name><surname>Kammler</surname><given-names>T</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><article-title>Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L</article-title><source> Phytotherapy research: PTR</source><year>2011</year><volume>25</volume><fpage>838</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">21089181</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Naghavi</surname><given-names>HR</given-names></name><name><surname>Vazirian</surname><given-names>M</given-names></name><name><surname>Shayeganpour</surname><given-names>A</given-names></name><name><surname>Rashidi</surname><given-names>H</given-names></name><name><surname>Khani</surname><given-names>M</given-names></name></person-group><article-title>Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam</article-title><source> Journal of clinical pharmacy and therapeutics</source><year>2001</year><volume>26</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">11679026</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Anti-anxiety studies on extracts of Passiflora incarnata Linneaus</article-title><source> Journal of ethnopharmacology</source><year>2001</year><volume>78</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">11694362</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>&#x0200e;M</surname><given-names>Nojoumi M</given-names></name></person-group><source>Investigation of Reaction Time after taking Passifloraincarnata (Passion Flower) &#x0200e;as an add-on therapy in patients with Generalized Anxiety Disorder and Healthy volunteers &#x0200e;&#x0200e;[dissertation]</source><year>2012</year><publisher-loc>[Tehran]</publisher-loc><publisher-name>Islamic Azad University of Pharmaceutical Sciences</publisher-name><lpage>154</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaTour</surname><given-names>MS</given-names></name><name><surname>Rotfeld</surname><given-names>HJ</given-names></name></person-group><article-title>There are threats and (maybe) fear-caused arousal: Theory and confusions of appeals to fear and fear arousal itself</article-title><source> Journal of advertising</source><year>1997</year><volume>26</volume><fpage>45</fpage><lpage>59</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambless</surname><given-names>DL</given-names></name><name><surname>Gracely</surname><given-names>EJ</given-names></name></person-group><article-title>Fear of fear and the anxiety disorders</article-title><source> Cognitive Therapy and Research</source><year>1989</year><volume>13</volume><fpage>9</fpage><lpage>20</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Association</surname><given-names>AP</given-names></name></person-group><source>Diagnostic and statistical manual of mental disorders (DSM-5&#x000ae;)</source><year>2013</year><publisher-loc>City</publisher-loc><publisher-name>American Psychiatric Pub</publisher-name></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes-Skelton</surname><given-names>SA</given-names></name><name><surname>Roemer</surname><given-names>L</given-names></name><name><surname>Orsillo</surname><given-names>SM</given-names></name></person-group><article-title>A randomized clinical trial comparing an acceptance-based behavior therapy to applied relaxation for generalized anxiety disorder</article-title><source> Journal of consulting and clinical psychology</source><year>2013</year><volume>81</volume><fpage>761</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">23647281</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;&#x0200e;Perna</surname><given-names>R</given-names></name></person-group><article-title>Benzodiazepines and antipsychotics: cognitive side effects</article-title><source> The Journal of head trauma rehabilitation</source><year>2004</year><volume>19</volume><fpage>516</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">15602314</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>V</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name></person-group><article-title>Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study</article-title><source> The British Journal of Psychiatry</source><year>2009</year><volume>195</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">19721109</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Newman</surname><given-names>MG</given-names></name><name><surname>Fisher</surname><given-names>AJ</given-names></name></person-group><article-title>Mediated moderation in combined cognitive behavioral therapy versus component treatments for generalized anxiety disorder</article-title><source> Journal of consulting and clinical psychology</source><year>2013</year><volume>81</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">23398493</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaiya</surname><given-names>SD</given-names></name><name><surname>Bujang</surname><given-names>JS</given-names></name><name><surname>Zakaria</surname><given-names>MH</given-names></name></person-group><article-title>Assessment of total phenolic, antioxidant, and antibacterial activities of Passiflora species</article-title><source>ScientificWorldJournal</source><year>2014</year><volume>2014</volume><fpage>167309</fpage><pub-id pub-id-type="pmid">25028673</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0200e;Simmen</surname><given-names>U</given-names></name><name><surname>Burkard</surname><given-names>W</given-names></name><name><surname>Berger</surname><given-names>K</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name><name><surname>Lundstrom</surname><given-names>K</given-names></name></person-group><article-title>Extracts and constituents of Hypericum perforatum inhibit the binding of vario us ligands to recombinant receptors expressed with the Semliki Forest virus system</article-title><source> Journal of Receptors and Signal Transduction</source><year>1999</year><volume>19</volume><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">10071750</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lolli</surname><given-names>LF</given-names></name><name><surname>Sato</surname><given-names>CM</given-names></name><name><surname>Romanini</surname><given-names>CV</given-names></name><name><surname>Villas-Boas</surname><given-names>Lde B</given-names></name><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>de</surname><given-names>Oliveira RM</given-names></name></person-group><article-title>Possible involvement of GABA A-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice</article-title><source> Journal of ethnopharmacology</source><year>2007</year><volume>111</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">17196350</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>K</given-names></name><name><surname>Rose</surname><given-names>T</given-names></name><name><surname>Fiebich</surname><given-names>B</given-names></name><name><surname>Kammler</surname><given-names>T</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><article-title>Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L</article-title><source> Phytotherapy research: PTR</source><year>2011</year><volume>25</volume><fpage>838</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">21089181</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslanargun</surname><given-names>P</given-names></name><name><surname>Cuvas</surname><given-names>O</given-names></name><name><surname>Dikmen</surname><given-names>B</given-names></name><name><surname>Aslan</surname><given-names>E</given-names></name><name><surname>Yuksel</surname><given-names>MU</given-names></name></person-group><article-title>Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia</article-title><source> Journal of anesthesia</source><year>2012</year><volume>26</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22048283</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movafegh</surname><given-names>A</given-names></name><name><surname>Alizadeh</surname><given-names>R</given-names></name><name><surname>Hajimohamadi</surname><given-names>F</given-names></name><name><surname>Esfehani</surname><given-names>F</given-names></name><name><surname>Nejatfar</surname><given-names>M</given-names></name></person-group><article-title>Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study</article-title><source> Anesthesia and analgesia</source><year>2008</year><volume>106</volume><fpage>1728</fpage><lpage>1732</lpage><pub-id pub-id-type="pmid">18499602</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimpfel</surname><given-names>W</given-names></name><name><surname>Koch</surname><given-names>K</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><article-title>Single dose effects of Pascoflair&#x000ae; on current source density (CSD) of human EEG</article-title><source> Neuroscience and Medicine</source><year>2012</year><volume>3</volume><fpage>130</fpage></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movafegh</surname><given-names>A</given-names></name><name><surname>Alizadeh</surname><given-names>R</given-names></name><name><surname>Hajimohamadi</surname><given-names>F</given-names></name><name><surname>Esfehani</surname><given-names>F</given-names></name><name><surname>Nejatfar</surname><given-names>M</given-names></name></person-group><article-title>Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study</article-title><source> Anesthesia and analgesia</source><year>2008</year><volume>106</volume><fpage>1728</fpage><lpage>1732</lpage><pub-id pub-id-type="pmid">18499602</pub-id></element-citation></ref></ref-list></back></article>